Bone Turnover Markers, n-Terminal Propeptide of Type I Procollagen and Tartrate-Resistant Acid Phosphatase Type 5b, for Predicting Castration Resistance in Prostate Cancer

被引:1
|
作者
Kano, Hiroshi [1 ]
Izumi, Kouji [1 ]
Nakagawa, Ryunosuke [1 ]
Toriumi, Ren [1 ]
Aoyama, Shuhei [1 ]
Kamijima, Taiki [1 ]
Makino, Tomoyuki [1 ]
Naito, Renato [1 ]
Iwamoto, Hiroaki [1 ]
Yaegashi, Hiroshi [1 ]
Kawaguchi, Shohei [1 ]
Shigehara, Kazuyoshi [1 ]
Nohara, Takahiro [1 ]
Mizokami, Atsushi [1 ]
机构
[1] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, 13-1 Takara Machi, Ishikawa 9208640, Japan
关键词
P1NP; TRACP-5b; castration-resistant prostate cancer; PROGRESSION; METASTASIS; CELLS;
D O I
10.3390/biomedicines12020292
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bone is a common site of prostate cancer metastasis. Bone turnover markers n-terminal propeptide of type I procollagen (P1NP) and tartrate-resistant acid phosphatase type 5b (TRACP-5b) are highly sensitive to bone remodeling activity. However, their prognostic significance as markers of prostate cancer is unknown. This study retrospectively examined the usefulness of P1NP and TRACP-5b as prognostic biomarkers. Castration-resistant prostate cancer recurrence-free survival (CFS) was estimated using the Kaplan-Meier method. A predictive model for CFS was constructed using multivariate analysis. This study enrolled 255 patients diagnosed with prostate cancer at Kanazawa University Hospital. The median follow-up was 115.1 months. Patients with both high serum P1NP and TRACP-5b levels, defined as having a poor bone turnover category (BTC), had significantly shorter CFS. Multivariate analysis identified Gleason score, metastasis, and BTC poor as predictors for castration resistance in prostate cancer. Using these three factors, a prognostic model was established, categorizing patients into low-risk (no or one factor) and high-risk (two or three factors) groups. In the low-risk group, the median CFS was not reached, contrasting with 19.1 months in the high-risk group (hazard ratio, 32.23, p < 0.001). Combining P1NP and TRACP-5b may better predict castration resistance.
引用
收藏
页数:12
相关论文
共 50 条
  • [11] Tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of bone resorption
    Halleen, Jussi M.
    Tiitinen, Sari L.
    Ylipahkala, Hannele
    Fagerlund, Katja M.
    Vaananen, H. Kalervo
    CLINICAL LABORATORY, 2006, 52 (9-10) : 499 - 509
  • [12] Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide
    Eastell, R.
    Rogers, A.
    Ni, X.
    Krege, J. H.
    OSTEOPOROSIS INTERNATIONAL, 2011, 22 (06) : 1927 - 1934
  • [13] Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide
    R. Eastell
    A. Rogers
    X. Ni
    J. H. Krege
    Osteoporosis International, 2011, 22 : 1927 - 1934
  • [14] Serum tartrate-resistant acid phosphatase 5b (TRACP 5b) as a marker of skeletal changes in prostate cancer
    Salminen, E
    Ala-Houhala, M
    Korpela, J
    Varpula, M
    Tiitinen, SL
    Halleen, JM
    Väänänen, HK
    ACTA ONCOLOGICA, 2005, 44 (07) : 742 - 747
  • [15] Comparison of serum tartrate-resistant acid phosphatase 5b with other markers of bone turnover in monitoring alendronate therapy.
    Alatalo, SL
    Ivaska, KK
    Cheng, S
    Schmidt-Gayk, H
    Uusi-Rasi, K
    Nenonen, A
    Kannus, P
    Sievänen, H
    Väänänen, HK
    Halleen, JM
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S316 - S317
  • [16] Comparison of serum tartrate-resistant acid phosphatase 5b with other markers of bone turnover in monitoring alendronate therapy.
    Halleen, JM
    Nenonen, AM
    Alatalo, SL
    Ivaska, KK
    Cheng, S
    Schmidt-Gayk, H
    Uusi-Rasi, K
    Heinonen, A
    Kannus, P
    Sievänen, H
    Väänänen, K
    JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S121 - S121
  • [17] Tartrate-resistant acid phosphatase isoform 5b (TRACP 5b) as a serum maker for cancer with bone metastasis
    Chao, Tsu-Yi
    Wu, Yi-Ying
    Janckila, Anthony J.
    CLINICA CHIMICA ACTA, 2010, 411 (21-22) : 1553 - 1564
  • [18] Tartrate-resistant acid phosphatase 5b as serum marker of bone metabolism in cancer patients
    Mose, S
    Menzel, C
    Kurth, AA
    Obert, K
    Breidert, I
    Borowsky, K
    Böttcher, HD
    ANTICANCER RESEARCH, 2003, 23 (3C) : 2783 - 2788
  • [19] Comparison of serum tartrate-resistant acid phosphatase type 5b assays and other bone resorption markers for monitoring raloxifene therapy
    Mochizuki, Y.
    Oishi, A.
    Igarashi, Y.
    Inaba, N.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S414 - S414
  • [20] Tartrate-resistant acid phosphatase 5b and C-terminal telopeptides of type I collagen as markers for diagnosis of aseptic loosening after total hip replacement
    Stefan Landgraeber
    Franz Löer
    Hansjörg Heep
    Tim Classen
    Florian Grabellus
    Martin Totsch
    Marius von Knoch
    Archives of Orthopaedic and Trauma Surgery, 2010, 130 : 441 - 445